Volume 6.18 | May 15

Mammary Cell News 6.18 May 15, 2014
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
Glutathione-Dependent and -Independent Oxidative Stress-Control Mechanisms Distinguish Normal Human Mammary Epithelial Cell Subsets
Scientists showed that purified normal human basal mammary epithelial cells maintain low levels of reactive oxygen species primarily by a glutathione-dependent but inefficient antioxidant mechanism that uses mitochondrial glutathione peroxidase 2. [Proc Natl Acad Sci USA] Abstract | Full Article
Listen Now: Podcast on ALDH in Breast Cancer Treatment Response
PUBLICATIONS (Ranked by impact factor of the journal)

Chloroquine Eliminates Cancer Stem Cells through Deregulation of Jak2 and DNMT1
Researchers report that chloroquine sensitizes triple negative breast cancer cells to paclitaxel through inhibition of autophagy and reduces the CD44+/CD24-/low cancer stem cell population in both preclinical and clinical settings. [Stem Cells] Abstract

A Novel Oncogenic Role of Inositol Phosphatase SHIP2 in ER-Negative Breast Cancer Stem Cells: Involvement of JNK/Vimentin Activation
Investigators showed that the percentage of SH2-containing-5′-inositol phosphatase-2 (SHIP2)+ cells was positively correlated with that of CD24CD44+ cells in 60 breast cancer specimens. Among 20 estrogen receptor (ER)-negative samples, 17 had greater SHIP2 expression in CD24CD44+ subpopulation than the remaining subpopulation. [Stem Cells] Abstract

Bone Marrow Endothelium-Targeted Therapeutics for Metastatic Breast Cancer
Researchers tested targeted delivery of therapeutic siRNA loaded in the E-selectin thioaptamer-conjugated multistage vector drug carrier to bone marrow for the treatment of breast cancer bone metastasis. [J Control Release] Abstract

p38 MAPK Inhibits Breast Cancer Metastasis through Regulation of Stromal Expansion
Researchers report that p38 activation in breast cancer cells inhibits tumor metastasis but does not substantially modulate primary tumor growth. Stable p38 knockdown in breast cancer cells suppressed NF-κB p65 activation, inhibiting miR-365 expression and resulting in increased IL-6 secretion. [Int J Cancer] Abstract

14-3-3τ Promotes Breast Cancer Invasion and Metastasis by Inhibiting RhoGDIα
Investigators identify a critical role for 14-3-3τ in promoting breast cancer metastasis, in part through binding to and inhibition of RhoGDIα, a negative regulator of Rho GTPases and metastasis suppressor. [Mol Cell Biol] Abstract

Mesenchymal Stem Cells Inhibit Breast Cancer Cell Migration and Invasion through Secretion of Tissue Inhibitor of Metalloproteinase-1 and -2
Scientists describe a mechanism by which mesenchymal stem cells may be anti-tumorigenic, through inhibition of breast cancer cell migration and invasion, an important part of metastasis. [Mol Carcinog] Abstract


Systemic Therapy for Patients with Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
The authors aimed to provide evidence-based recommendations to practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2-positive advanced breast cancer. [J Clin Oncol] Abstract

Two Histopathologically Different Diseases: Hormone Receptor-Positive and Hormone Receptor-Negative Tumors in HER2-Positive Breast Cancer
The authors investigated various histopathologic features of human epidermal growth factor 2 (HER2)-positive breast cancer and their correlation with hormone receptor status. They retrospectively analyzed tumors of 450 HER2-positive breast cancer patients treated with chemotherapy and one year of trastuzumab. [Breast Cancer Res Treat] Abstract

Learn to Enumerate Mammospheres & Tumorspheres Cultured in MammoCult: Watch Procedure Now
A Fine-Scale Dissection of the DNA Double-Strand Break Repair Machinery and Its Implications for Breast Cancer Therapy
The authors review the latest knowledge on the two DNA double-strand break-repair pathways, homologous recombination and non-homologous end joining in human, describing in detail the functions of their components and the key mechanisms contributing to the repair. [Nucleic Acids Res] Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Puma Biotechnology Expands Cohort in Phase II Trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients
Puma Biotechnology, Inc. has expanded the first cohort from its Phase II clinical trial of its lead drug candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket trial). [Puma Biotechnology, Inc.] Press Release

Advaxis to Initiate Clinical Development of ADXS-cHER2 Immunotherapy to Treat Pediatric Bone Cancer
Advaxis, Inc. announced it intends to initiate a clinical development program with its product candidate, ADXS-cHER2, for the treatment of pediatric osteosarcoma. ADXS-cHER2 is an immunotherapy that targets the HER2 oncogene, which is overexpressed in certain solid-tumor cancers, including pediatric bone cancer and breast cancer. [Advaxis, Inc.] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUORTM can help.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW European Molecular Biology Organization (EMBO) Conference: Stem Cells in Cancer and Regenerative Medicine
October 9-12, 2014
Heidelberg, Germany

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Positions – Breast Cancer, Mouse Models, Tumor Microenvironment (National Cancer Institute)

Postdoctoral Training Fellow – Breast Cancer Functional Genomics (Institute of Cancer Research)

Postdoctoral Position – Breast Cancer Research (University of Oklahoma Health Sciences Center)

Postdoctoral Fellow – Cancer Biology (University of Cincinnati)

Postdoctoral Fellow – Mechanisms that Contribute to Metastases of Breast Cancer Cells (Icahn School of Medicine at Mount Sinai)

PhD Position – Breast Cancer Translational Research Laboratory (Jules Bordet Institute)

Postdoctoral Position in Stem Cell and Cancer (Harvard Medical School)

Junior Faculty Position – Breast Pathology (Northwestern University)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Research Technologist – hPSC (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Mammary Cell News: Archives | Events | Contact Us